Clinical trial
Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer…
NCT00365144 · University of California, San Francisco, Other · Completed
Key facts
| NCT number | NCT00365144 |
|---|---|
| Title | Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine |
| Official title | A Phase II Trial of Bevacizumab Plus Erlotinib for Patients With Metastatic Gemcitabine-Refractory Pancreatic Cancer |
| Lead sponsor | University of California, San Francisco, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Biological, Drug, Other |
| Interventions | bevacizumab, erlotinib hydrochloride, laboratory biomarker analysis |
| Enrollment | 36 |
| Start date | Feb 1, 2006 |
| Primary completion | Jan 1, 2009 |
| Completion | Mar 1, 2010 |
| First posted | Aug 17, 2006 |
| Last update posted | Jan 19, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: